| Year |
Citation |
Score |
| 2023 |
Arrieta VA, Duerinck J, Burdett KB, Habashy KJ, Geens W, Gould A, Schwarze JK, Dmello C, Kim KS, Saganty R, Chen L, Moscona A, McCord M, Lee-Chang C, Horbinski CM, et al. ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-Guided Analysis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37939133 DOI: 10.1158/1078-0432.CCR-23-1889 |
0.511 |
|
| 2023 |
McCord M, Jamshidi P, Thirunavu V, Santana-Santos L, Vormittag-Nocito E, Dittman D, Parker S, Baczkowski J, Jennings L, Walshon J, McCortney K, Galbraith K, Zhang H, Lukas RV, Stupp R, et al. Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results. Acta Neuropathologica Communications. 11: 175. PMID 37919784 DOI: 10.1186/s40478-023-01680-0 |
0.496 |
|
| 2023 |
Budhiraja S, Najem H, Tripathi S, Wadhawani NR, Horbinski C, McCord M, Lenzen AC, Heimberger AB, DeCuypere M. Immunobiology and Cytokine Modulation of the Pediatric Brain Tumor Microenvironment: A Scoping Review. Cancers. 15. PMID 37509316 DOI: 10.3390/cancers15143655 |
0.458 |
|
| 2023 |
Jamshidi P, McCord M, Galbraith K, Santana-Santos L, Jennings LJ, Snuderl M, Horbinski C. Variant allelic frequency of driver mutations predicts success of genomic DNA methylation classification in central nervous system tumors. Acta Neuropathologica. 145: 365-367. PMID 36700952 DOI: 10.1007/s00401-023-02542-8 |
0.512 |
|
| 2022 |
McCord M, Bartom E, Burdett K, Baran A, Eckerdt FD, Balyasnikova IV, McCortney K, Sears T, Cheng SY, Sarkaria JN, Stupp R, Heimberger AB, Ahmed A, James CD, Horbinski C. Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts. Cancers. 14. PMID 36428586 DOI: 10.3390/cancers14225494 |
0.503 |
|
| 2022 |
Santana-Santos L, Kam KL, Dittmann D, De Vito S, McCord M, Jamshidi P, Fowler H, Wang X, Aalsburg AM, Brat DJ, Horbinski C, Jennings LJ. Validation of Whole Genome Methylation Profiling Classifier for Central Nervous System Tumors. The Journal of Molecular Diagnostics : Jmd. PMID 35605901 DOI: 10.1016/j.jmoldx.2022.04.009 |
0.502 |
|
| 2022 |
Arrieta VA, Chen AX, Kane JR, Kang SJ, Kassab C, Dmello C, Zhao J, Burdett KB, Upadhyayula PS, Lee-Chang C, Shilati J, Jaishankar D, Chen L, Gould A, Zhang D, ... ... McCord M, et al. Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nature Cancer. PMID 35149861 DOI: 10.1038/s43018-022-00343-8 |
0.491 |
|
| 2022 |
Pratt D, Abdullaev Z, Papanicolau-Sengos A, Ketchum C, Panneer Selvam P, Chung HJ, Lee I, Raffeld M, Gilbert MR, Armstrong TS, Pytel P, Borys E, Klonoski JM, McCord M, Horbinski C, et al. High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13. Acta Neuropathologica. PMID 35103816 DOI: 10.1007/s00401-022-02404-9 |
0.559 |
|
| 2021 |
Arrieta VA, Chen AX, Kane JR, Kang SJ, Kassab C, Dmello C, Zhao J, Burdett KB, Upadhyayula PS, Lee-Chang C, Shilati J, Jaishankar D, Chen L, Gould A, Zhang D, ... ... McCord M, et al. ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nature Cancer. 2: 1372-1386. PMID 35121903 DOI: 10.1038/s43018-021-00260-2 |
0.537 |
|
| 2021 |
McCord M, Lukas RV, Amidei C, Demars N, Gelb A, Buck J, Sachdev S, Feldman A, Tate M, Dixit K, Brat DJ, Jennings L, Horbinski C. Disappearance of MMR-deficient subclones after controlled IL-12 and PD-1 inhibition in a glioma patient. Neuro-Oncology Advances. 3: vdab045. PMID 34250480 DOI: 10.1093/noajnl/vdab045 |
0.441 |
|
| 2020 |
McCord M, Steffens A, Javier R, Kam KL, McCortney K, Horbinski C. The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas. Acta Neuropathologica Communications. 8: 15. PMID 32051040 DOI: 10.1186/S40478-020-0892-2 |
0.538 |
|
| 2020 |
Drumm MR, Dixit KS, Grimm S, Kumthekar P, Lukas RV, Raizer JJ, Stupp R, Chheda MG, Kam KL, McCord M, Sachdev S, Kruser T, Steffens A, Javier R, McCortney K, et al. Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas. Neuro-Oncology. 22: 470-479. PMID 31711239 DOI: 10.1093/Neuonc/Noz216 |
0.446 |
|
| Show low-probability matches. |